JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2006; 48:47-55, doi:10.1016/j.jacc.2006.05.063 (Published online 16 October 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Abbreviations List
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, S.-F.
Right arrow Articles by Schmidt, A. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Yan, S.-F.
Right arrow Articles by Schmidt, A. M.

Protein Kinase C ß/Early Growth Response-1 Pathway

A Key Player in Ischemia, Atherosclerosis, and Restenosis

Shi-Fang Yan, MD*, Evis Harja, MD, Martin Andrassy, MD, Tomoyuki Fujita, MD and Ann Marie Schmidt, MD

Department of Surgery, Columbia University, New York, New York


Figure 1
View larger version (46K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Protein kinase Cß-early growth response-1 (PKCß-Egr-1): implications for vascular stress. In this review, we provided the experimental evidence linking PKCß and Egr-1 to the pathogenesis of tissue injury. Studies support the premise that both acute stresses, such as that induced by hypoxia/hypoxemia and ischemia/reperfusion, as well as chronic stresses, such as that which occurs in atherosclerosis and restenosis, activate PKC, particularly the ß isoform. PKCß-mediated up-regulation of Egr-1 results in expression of cytokines, chemokines, procoagulant, and adhesion molecules; processes that lead to amplification of vascular inflammation, migration, and proliferation. Once set in motion, such processes, dependent on PKCß-Egr-1, lead to chronic vascular dysfunction and, ultimately, if left unchecked, tissue injury. Novel inhibitors of PKCß in clinical trials may hold promise for the treatment of these acute and chronic vascular diseases.

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.